<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Thromb Thrombolysis</journal-id><journal-id journal-id-type="iso-abbrev">J Thromb Thrombolysis</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of thrombosis and thrombolysis</journal-title></journal-title-group><issn pub-type="ppub">0929-5305</issn><issn pub-type="epub">1573-742X</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10233612</article-id><article-id pub-id-type="pmcid-ver">PMC10233612.1</article-id><article-id pub-id-type="pmcaid">10233612</article-id><article-id pub-id-type="pmcaiid">10233612</article-id><article-id pub-id-type="manuscript-id">NIHMS1896159</article-id><article-id pub-id-type="pmid">36757644</article-id><article-id pub-id-type="doi">10.1007/s11239-023-02774-1</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1896159</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1896159</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Martin</surname><given-names initials="K">Karlyn</given-names></name><degrees>MD MS</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lancki</surname><given-names initials="N">Nicola</given-names></name><degrees>MPH</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="C">Celina</given-names></name><degrees>BS</degrees><xref rid="A11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eyster</surname><given-names initials="ME">M. Elaine</given-names></name><degrees>MD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sanfilippo</surname><given-names initials="K">Kristen</given-names></name><degrees>MD MPHS</degrees><xref rid="A4" ref-type="aff">4</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Woller</surname><given-names initials="IA">Isabela A.</given-names></name><degrees>BS</degrees><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Woller</surname><given-names initials="SC">Scott C.</given-names></name><degrees>MD</degrees><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kreuziger</surname><given-names initials="LB">Lisa Baumann</given-names></name><degrees>MD MS</degrees><xref rid="FN1" ref-type="author-notes">*</xref><xref rid="A8" ref-type="aff">8</xref><xref rid="A9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rosovsky</surname><given-names initials="RP">Rachel P.</given-names></name><degrees>MD MPH</degrees><xref rid="A10" ref-type="aff">10</xref><xref rid="A11" ref-type="aff">11</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine</aff><aff id="A2"><label>2</label>Northwestern University Feinberg School of Medicine</aff><aff id="A3"><label>3</label>Penn State Hershey Medical Center, Hershey, PA</aff><aff id="A4"><label>4</label>Washington University St. Louis School of Medicine, Saint Louis, MO</aff><aff id="A5"><label>5</label>Saint Louis Veterans Administration Medical Center, Saint Louis, MO</aff><aff id="A6"><label>6</label>Loyola University, Chicago, IL</aff><aff id="A7"><label>7</label>Department of Medicine, Intermountain Medical Center, Murray UT; Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT</aff><aff id="A8"><label>8</label>Blood Research Institute, Versiti, Milwaukee, WI</aff><aff id="A9"><label>9</label>Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI</aff><aff id="A10"><label>10</label>Department of Medicine, Division of Hematology, Massachusetts General Hospital and Harvard Medical School, Boston, MA</aff><aff id="A11"><label>11</label>Department of Medicine, Division of Hematology, Massachusetts General Hospital and Harvard Medical School, Boston, MA</aff><author-notes><fn id="FN1"><label>*</label><p id="P1">co senior authors</p></fn><corresp id="CR1">Corresponding author: Karlyn Martin MD MS, 645 N Michigan Ave, Suite 1020, Chicago, IL 60611, Phone: (312) 695-4545, <email>Karlyn.martin@northwestern.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>5</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>09</day><month>2</month><year>2023</year></pub-date><volume>55</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">437058</issue-id><fpage>685</fpage><lpage>690</lpage><pub-history><event event-type="nihms-submitted"><date><day>10</day><month>05</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 12:25:14.010"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1896159.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="correction-forward" xml:lang="en" journal-id="J Thromb Thrombolysis" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="36995647"><article-title>Correction to: DOAC compared with warfarin for VTE in patients with obesity: a retrospective cohort study conducted through the VENUS network.</article-title><date><day>30</day><month>3</month><year>2023</year></date><source>J Thromb Thrombolysis</source><pub-id pub-id-type="pmid">36995647</pub-id></related-article><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P2">The effectiveness and safety of direct oral anticoagulants (DOAC) compared with warfarin remains uncertain in obese patients. We assessed the comparative effectiveness and safety of DOACs with warfarin for the treatment of VTE among obese patients.</p></sec><sec id="S2"><title>Methods:</title><p id="P3">This multi-center retrospective cohort study included adults with a BMI &#8805;35 kg/m<sup>2</sup> or weight &#8805;120 kg prescribed either DOAC (apixaban, dabigatran, edoxaban, rivaroxaban) or warfarin for a VTE diagnosis. The primary outcome was the 12-month rate of recurrent VTE. The secondary outcome was the 12-month rate of major bleeding.</p></sec><sec id="S3"><title>Results:</title><p id="P4">Among 5,626 patients, 67% were prescribed warfarin and 33% were prescribed a DOAC. The 12-month VTE recurrence rate was 3.6% (67/1823) for patients treated with DOAC compared with 3.8% (143/3664) for patients treated with warfarin [odds ratio for recurrent VTE on warfarin versus DOAC (OR) (95% CI) =1.06 (0.79, 1.44)]. The 12-month major bleeding rate was 0.5% (10/1868) for patients on DOAC versus 2.4% (89/3758) on warfarin [OR = 4.25 (2.19, 8.22)]. Similar proportions of recurrent VTE occurred across BMI thresholds on DOAC and warfarin: for BMI &#8805;35 kg/m<sup>2</sup> (N=5412), 3.6% vs 3.8%, respectively [OR 1.08 (0.80, 1.46)]; for BMI &#8805;40 kg/m<sup>2</sup> (N=2321), 4.4% vs 3.5%, respectively [OR 0.80 (0.51, 1.26)]; and for BMI &#8805;50 kg/m<sup>2</sup> (N=560), 3.1% vs 3.7%, respectively [OR 1.18 (0.39, 3.56)].</p></sec><sec id="S4"><title>Conclusion:</title><p id="P5">Similar proportions of recurrent VTE occurred in patients with obesity treated for VTE with DOACs and warfarin. DOACs were associated with lower major bleeding compared to warfarin in patients with obesity and VTE.</p></sec></abstract><kwd-group><kwd>venous thromboembolism</kwd><kwd>obesity</kwd><kwd>anticoagulants</kwd><kwd>factor Xa inhibitors</kwd><kwd>warfarin</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>